methyl 2-(4-(4-(butylcarbamoyl)-2-((2,4-dichlorophenyl)sulfonamido)phenoxy)-3-methoxyphenyl)-2,2-difluoroacetate | 1356844-84-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-(4-(butylcarbamoyl)-2-((2,4-dichlorophenyl)sulfonamido)phenoxy)-3-methoxyphenyl)-2,2-difluoroacetate
• CAS: 1356844-84-2
• 化学式: C₂₇H₂₆Cl₂F₂N₂O₇S
• 分子量: 631.481
• InChiKey: DHPSWCLLEFGTDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.39
• 重原子数：
  41.0
• 可旋转键数：
  12.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  120.03
• 氢给体数：
  2.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-(4-(butylcarbamoyl)-2-((2,4-dichlorophenyl)sulfonamido)phenoxy)-3-methoxyphenyl)-2,2-difluoroacetate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 以47%的产率得到2-[4-[4-(Butylcarbamoyl)-2-[(2,4-dichlorophenyl)sulfonylamino]phenoxy]-3-methoxyphenyl]-2,2-difluoroacetic acid
  参考文献：
  名称：

  Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism

  摘要：

  We have previously reported that optimization of a series of phenylacetic acid derivatives led to the discovery of CRTH2 and DP dual antagonists, such as AMG 009 and AMG 853. During the optimization process, we discovered that minor structural modifications also afforded potent and selective CRTH2 or DP antagonists. Here we report the structure-activity relationship that led to the discovery of selective CRTH2 antagonists such as 2 and 17, and selective DP antagonists, such as 4 and 5. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.123
• 作为产物：
  描述：

  3-硝基-4-氯苯甲酰氯 在 2,6-二甲基吡啶 、 二乙胺基三氟化硫 、 palladium on activated charcoal 、 氢气 、 caesium carbonate 、 戴斯-马丁氧化剂 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 二甲基亚砜 、 乙酸乙酯 、 1,2-二氯乙烷 、 苯 为溶剂， 反应 162.5h， 生成 methyl 2-(4-(4-(butylcarbamoyl)-2-((2,4-dichlorophenyl)sulfonamido)phenoxy)-3-methoxyphenyl)-2,2-difluoroacetate
  参考文献：
  名称：

  Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism

  摘要：

  We have previously reported that optimization of a series of phenylacetic acid derivatives led to the discovery of CRTH2 and DP dual antagonists, such as AMG 009 and AMG 853. During the optimization process, we discovered that minor structural modifications also afforded potent and selective CRTH2 or DP antagonists. Here we report the structure-activity relationship that led to the discovery of selective CRTH2 antagonists such as 2 and 17, and selective DP antagonists, such as 4 and 5. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.123